Kailera Therapeutics, Inc. Common Stock (KLRA) — Cash Flow-to-Debt Ratio
Kailera Therapeutics, Inc. Common Stock (KLRA) has a Cash Flow-to-Debt Ratio of -0.11x as of December 2025, meaning its operating cash flow of $-120.21 Million could theoretically repay 0% of its total liabilities ($1.05 Billion) in one year. See working capital to net assets of Kailera Therapeutics, Inc. Common Stock to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kailera Therapeutics, Inc. Common Stock Cash Flow-to-Debt Ratio (2025–2025)
Historical debt coverage capacity for Kailera Therapeutics, Inc. Common Stock across 1 annual periods. Also explore how fast is Kailera Therapeutics, Inc. Common Stock growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Kailera Therapeutics, Inc. Common Stock (2025–2025)
Year-by-year debt coverage analysis for Kailera Therapeutics, Inc. Common Stock. For market capitalisation and broader financial context, see how much is Kailera Therapeutics, Inc. Common Stock worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | $-120.21 Million | $1.05 Billion | — |